Targeting CBP and p300: Emerging Anticancer Agents

Domiziana Masci1, Michela Puxeddu2, Romano Silvestri2

  • 1Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy.

PubMed

Insights

Researchers are developing small molecules to inhibit CBP and p300 co-activators, crucial for Wnt/β-catenin signaling, to treat cancers driven by this pathway.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Drug Discovery

Background:

  • CBP and p300 are key transcriptional co-activators regulating vital cellular processes and signaling pathways like Wnt/β-catenin.
  • Dysregulated Wnt/β-catenin signaling is implicated in various cancers, driving tumor proliferation, migration, and invasion.
  • Targeting the interaction between β-catenin and CBP/p300 presents a promising strategy for cancer therapy.

Purpose of the Study:

  • To review recent advancements (2010-present) in developing small molecule inhibitors targeting CBP/β-catenin and p300/β-catenin interactions.
  • To explore the therapeutic potential of CBP/p300 bromodomain and histone acetyltransferase inhibitors in cancer treatment.
  • To provide an overview of strategies targeting CBP and p300 in Wnt/β-catenin-driven oncogenesis.

Main Methods:

  • PubMed literature search for original research articles from 2010 to date.
  • Focus on studies developing specific and non-specific inhibitors of CBP/β-catenin and p300/β-catenin interactions.
  • Inclusion of research on CBP/p300 bromodomain and histone acetyltransferase inhibitors.

Main Results:

  • Significant progress has been made in identifying small molecules that inhibit CBP/β-catenin and p300/β-catenin interactions.
  • Various CBP/p300 inhibitors show therapeutic potential by disrupting oncogenic signaling pathways.
  • Research highlights the role of these co-activators in Wnt/β-catenin-driven cancers.

Conclusions:

  • Targeting CBP and p300 interactions with β-catenin offers a viable therapeutic approach for Wnt/β-catenin-driven cancers.
  • CBP/p300 inhibitors, including bromodomain and HAT inhibitors, represent a promising avenue for novel cancer treatments.
  • Further research into these targeted therapies is crucial for effective cancer intervention.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K